IRIDEX Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
IRIDEX Stock Forecast and Price Target
IRIDEX's most recent price target of $2.00 for 2024 was provided by renowned analysts over the past few months, with an average prediction of $2.00. If this prediction is correct, IRIDEX's stock could fall by -29.82 percent from its current trading price. The potential decrease for the stock is $2.00 per share, with a possible range of $2.00 to $2.00. If you're looking to buy IRIDEX stock, you may also want to check out its rivals.
-29.82% Downside
IRIDEX Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, IRIDEX's Price has grown by 100.00%, from $0.00 to $0.00. For the next year, analysts are expecting Fair Value to reach $3.06 – an increase of 100.00%. Over the next seven years, experts predict that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF88.87 | Buy/Sell | CHF105.00 | 21.10% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$27.70 | Buy/Sell | $32.87 | 10.11% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$937.61 | Buy/Sell | $961.26 | 11.99% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.56k | Buy/Sell | ¥2.64k | 29.97% |
| AFX Stock Forecast | Carl Zeiss Meditec | Hold |
18
|
97.35€ | Buy/Sell | 95.38€ | 7.86% |
IRIDEX Revenue Forecast for 2023 - 2025 - 2030
In the last year, IRIDEX's Revenue has grown by 5.70%, from $53.90M to $56.97M. According to 2 prominent analysts, IRIDEX's Revenue will fall by 3.00% in the next year, reaching $55.26M. By 2030, professionals believe that IRIDEX's Revenue will decrease by 2.95%, reaching $55.29M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IART Stock Forecast | Integra LifeSciences Holdings | Hold |
16
|
$28.75 | Buy/Sell | $46.60 | 51.30% |
| ANIK Stock Forecast | Anika Therapeutics | Outperform |
10
|
$27.59 | Buy/Sell | $27.33 | 15.98% |
| UTMD Stock Forecast | Utah Medical Products | - |
18
|
$73.10 | Buy/Sell | $0.00 | -100.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LBIRD Stock Forecast | Lumibird | Buy |
16
|
12.60€ | Buy/Sell | 20.55€ | 40.87% |
| FONR Stock Forecast | FONAR | - |
16
|
$22.17 | Buy/Sell | $0.00 | -100.00% |
| AVGR Stock Forecast | Avinger | Outperform |
9
|
$3.84 | Buy/Sell | $5.00 | 30.21% |
IRIDEX EBITDA Forecast for 2023 - 2025 - 2030
In the last year, IRIDEX's EBITDA has grown by 4.90%, rising from $-6.73M to $-7.06M. In the next year, 1 analysts estimate that IRIDEX's EBITDA will decrease by 68.84%, reaching $-2.20M. According to professional forecasts, in 2030, IRIDEX's EBITDA will decrease by 38.38%, reaching $-4.35M.
IRIDEX EBIT Forecast for 2023 - 2025 - 2030
In the last year, IRIDEX's EBIT has grown, rising from $-7.53M to $-7.54M – a growth of 0.13%. In the next year, analysts believe that EBIT will reach $-7.61M – an increase of 0.93%. Professionals believe that By 2030, IRIDEX's EBIT will fall to $-6.31M – a 16.36% decrease from its current value.
IRIDEX EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, IRIDEX's EPS has grown by 100.00%, from $-0.46 to $0.00. For the next year, analysts are expecting EPS to reach $-0.45 – an increase of 100.00%. Over the next seven years, experts predict that EPS will grow by 100.00%.
.jpg)